{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:18:14Z","timestamp":1785557894595,"version":"3.56.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ck0106899"],"award-info":[{"award-number":["JP24ck0106899"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Funds","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The goal of surgery for patients with newly diagnosed glioblastoma (GBM) is maximum safe resection of the contrast-enhancing (CE) lesion on magnetic resonance imaging. However, there is no consensus on the efficacy of FLAIRectomy, which is defined as the possible resection of fluid-attenuated inversion recovery (FLAIR)-hyperintense lesions surrounding the CE lesion. Although retrospective analyses suggested the potential benefits of FLAIRectomy, such outcomes have not been confirmed by prospective studies. Therefore, we planned a multicenter, open-label, randomized controlled phase III trial to evaluate the efficacy of FLAIRectomy compared with gross total resection of CE lesions in patients with newly diagnosed GBM. The primary endpoint is overall survival. In total, 130 patients will be enrolled from 47 institutions over 5\u00a0years. This trial has been registered at the Japan Registry of Clinical Trials (study number jRCT1031230245).<\/jats:p>","DOI":"10.1093\/jjco\/hyae130","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T13:52:09Z","timestamp":1726667529000},"page":"75-79","source":"Crossref","is-referenced-by-count":5,"title":["Protocol digest of a phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery-hyperintense lesion on MRI for newly diagnosed supratentorial glioblastoma: JCOG2209 (FLAMINGO)"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-4972","authenticated-orcid":false,"given":"Yuta","family":"Sekino","sequence":"first","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery , Faculty of Medicine, , 2-2-2 iida-nishi, Yamagata-shi, Yamagata 990-9585,","place":["Japan"]},{"name":"Yamagata University , Faculty of Medicine, , 2-2-2 iida-nishi, Yamagata-shi, Yamagata 990-9585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiyo","family":"Shibahara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kitasato University School of Medicine , 1-15-1 Kitazato, Minami Ward, Sagamihara, Kanagawa 252-0329,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5100-3863","authenticated-orcid":false,"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sekita","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Radiology , Division of Radiation Oncology, Faculty of Medicine, , 2-2-2 iida-nishi, Yamagata-shi, Yamagata 990-9585,","place":["Japan"]},{"name":"Yamagata University , Division of Radiation Oncology, Faculty of Medicine, , 2-2-2 iida-nishi, Yamagata-shi, Yamagata 990-9585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7817-624X","authenticated-orcid":false,"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Asahikawa Medical University , 2-1-1-1 Midorigaoka Higashi, Asahikawa City, Hokkaido 078-8510,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kumabe","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kitasato University School of Medicine , 1-15-1 Kitazato, Minami Ward, Sagamihara, Kanagawa 252-0329,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Shibahara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kyorin University Faculty of Medicine , 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kyorin University Faculty of Medicine , 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4645","authenticated-orcid":false,"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyoto University Graduate School of Medicine , Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Brain Tumor Study Group (BTSG) of the Japan Clinical Oncology Group (JCOG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo City, Tokyo 104-0045,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2025010815265069100_ref1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"key":"2025010815265069100_ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2176\/nmc.sup.2017-0001","article-title":"Brain tumor registry of Japan (2005\u20132008)","volume":"57","year":"2017","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2025010815265069100_ref3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2025010815265069100_ref4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg"},{"key":"2025010815265069100_ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.jns10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J Neurosurg"},{"key":"2025010815265069100_ref6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025010815265069100_ref7","doi-asserted-by":"publisher","first-page":"vdaa114","DOI":"10.1093\/noajnl\/vdaa114","article-title":"TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma","volume":"2","author":"Kikuchi","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2025010815265069100_ref8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","article-title":"Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms","volume":"66","author":"Kelly","year":"1987","journal-title":"J Neurosurg"},{"key":"2025010815265069100_ref9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/wnl.30.9.907","article-title":"Assumptions in the radiotherapy of glioblastoma","volume":"30","author":"Hochberg","year":"1980","journal-title":"Neurology"},{"key":"2025010815265069100_ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2020.10.JNS203366","article-title":"Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma","volume":"136","author":"Vivas-Buitrago","year":"2022","journal-title":"J Neurosurg"},{"key":"2025010815265069100_ref11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","article-title":"The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection?","volume":"124","author":"Li","year":"2016","journal-title":"J Neurosurg"},{"key":"2025010815265069100_ref12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-017-2559-9","article-title":"Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience","volume":"135","author":"Pessina","year":"2017","journal-title":"J Neurooncol"},{"key":"2025010815265069100_ref13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1245\/s10434-016-5635-z","article-title":"Dynamics of FLAIR volume changes in glioblastoma and prediction of survival","volume":"24","author":"Grossman","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2025010815265069100_ref14","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1016\/j.wneu.2019.12.130","article-title":"T2 fluid-attenuated inversion recovery resection for glioblastoma involving eloquent brain areas facilitated through awake craniotomy and clinical outcome","volume":"135","author":"Lu","year":"2020","journal-title":"World Neurosurg"},{"key":"2025010815265069100_ref15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.wneu.2019.04.092","article-title":"Association between supratotal glioblastoma resection and patient survival: a systematic review and meta-analysis","volume":"127","author":"Incekara","year":"2019","journal-title":"World Neurosurg"},{"key":"2025010815265069100_ref16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-020-03556-y","article-title":"A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma","volume":"148","author":"Jackson","year":"2020","journal-title":"J Neurooncol"},{"key":"2025010815265069100_ref17","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/j.wneu.2023.07.020","article-title":"Supratotal resection: an emerging concept of glioblastoma multiforme surgery-systematic review and meta-analysis","volume":"179","author":"Aziz","year":"2023","journal-title":"World Neurosurg"},{"key":"2025010815265069100_ref18","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025010815265069100_ref19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"},{"key":"2025010815265069100_ref20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"2025010815265069100_ref21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0197-2456(82)90022-8","article-title":"An aid to data monitoring in long-term clinical trials","volume":"3","author":"Halperin","year":"1982","journal-title":"Control Clin Trials"},{"key":"2025010815265069100_ref22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/sim.4780121516","article-title":"Applying Bayesian ideas in drug development and clinical trials","volume":"12","author":"Spiegelhalter","year":"1993","journal-title":"Stat Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/1\/75\/59157275\/hyae130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/1\/75\/59157275\/hyae130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:27:05Z","timestamp":1736350025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/1\/75\/7759642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,17]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae130","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,9,17]]}}}